WilmerHale Reps Disarm Therapeutics in $30M Series A Financing

• 10.5.2017

On September 19, 2017, Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, announced the recent completion of a $30 million Series A financing. The round was led by Atlas Venture, with co-investors Lightstone Ventures and AbbVie Ventures. Disarm was co-founded, seeded and incubated in 2016 by Atlas Venture, together with Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University in St. Louis.

Stuart Falber led the WilmerHale team representing Disarm in this transaction, which also included Stephanie Singer and Brett Bromann.

Read Disarm's press release for more information.